PCSK9 and neoplasm: Genetic deletion or pharmacological inhibition of PCSK9 in tumor cells enhances the antitumor activity of CD8+ T cells, indicating that the PCSK9/LDLR axis is a potential therapeutic target for cancer immunotherapy [63].